An ISO9001 Certified Supplier of Pharmaceutical Ingredients and Specialty Chemicals

APHEXDA®

Drug Information Related Patent
Hold Company
BIOLINERX LTD
Learn More
Dosage and Administration
POWDER;SUBCUTANEOUS
Specification
EQ 62MG BASE/VIAL
Indication
Aphexda® is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.
Use
Instructions for Use
API
MOTIXAFORTIDE ACETATE
API Structure
We Supply
MOTIXAFORTIDE
Drug Patent
Patent NoExpiration Date
122572852041/12/29
122687252041/12/29
API Patent
Patent NoExpiration Date
122572852041/12/29
122687252041/12/29

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION
CONTACT US
  • Tel:
  • E-mail:
  • Address:
  • WhatsAPP
    WhatsAPP
Privacy Policy | Cookie Policy
Copyright © Protheragen. All Rights Reserved.
Member of
dcat
CERTIFICATION
dcat
dcat dcat dcat dcat
Top